ZA200900155B - Method of immunisation against the four serotypes of dengue - Google Patents

Method of immunisation against the four serotypes of dengue

Info

Publication number
ZA200900155B
ZA200900155B ZA200900155A ZA200900155A ZA200900155B ZA 200900155 B ZA200900155 B ZA 200900155B ZA 200900155 A ZA200900155 A ZA 200900155A ZA 200900155 A ZA200900155 A ZA 200900155A ZA 200900155 B ZA200900155 B ZA 200900155B
Authority
ZA
South Africa
Prior art keywords
serotypes
dengue
immunisation against
immunisation
Prior art date
Application number
ZA200900155A
Other languages
English (en)
Inventor
Bruno Guy
Veronique Barban
Remi Forrat
Jean Lang
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of ZA200900155B publication Critical patent/ZA200900155B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200900155A 2006-07-12 2007-07-11 Method of immunisation against the four serotypes of dengue ZA200900155B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0606324A FR2903605A1 (fr) 2006-07-12 2006-07-12 Methode d'immunisation contre les quatres serotypes de la dengue

Publications (1)

Publication Number Publication Date
ZA200900155B true ZA200900155B (en) 2010-03-31

Family

ID=37866217

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200900155A ZA200900155B (en) 2006-07-12 2007-07-11 Method of immunisation against the four serotypes of dengue

Country Status (16)

Country Link
US (2) US7718357B2 (es)
EP (1) EP2043680A1 (es)
JP (1) JP5295956B2 (es)
KR (1) KR20090027759A (es)
CN (1) CN101489585B (es)
AR (1) AR061887A1 (es)
AU (1) AU2007274100B2 (es)
BR (1) BRPI0712878A2 (es)
CA (1) CA2656349A1 (es)
FR (1) FR2903605A1 (es)
IL (1) IL196331A0 (es)
MX (1) MX2009000369A (es)
MY (1) MY169275A (es)
TW (1) TWI400333B (es)
WO (1) WO2008007021A1 (es)
ZA (1) ZA200900155B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080193477A1 (en) * 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
WO2009109550A1 (en) 2008-03-05 2009-09-11 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
CA2770888C (en) 2009-08-31 2020-04-14 Gen-Probe Incorporated Dengue virus assay
SG189048A1 (en) 2010-10-29 2013-05-31 Merck Sharp & Dohme Recombinant subunit dengue virus vaccine
EP2877208B1 (en) * 2012-07-24 2021-05-12 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
JP2015524422A (ja) 2012-07-24 2015-08-24 サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ ワクチン組成物
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
TW201620546A (zh) * 2014-09-02 2016-06-16 賽諾菲巴斯德公司 疫苗組合物
BR112017028212A2 (pt) 2015-07-03 2018-09-11 Sanofi Pasteur vacinação concomitante contra dengue e febre amarela
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
CA3111332A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
BR112022001476A2 (pt) 2019-08-16 2023-10-03 Takeda Vaccines Inc Uso de uma vacina contra hepatite a e uma composição de vacina contra dengue ou uma dose unitária de uma composição de vacina contra dengue, combinação de vacina e kit
WO2021174059A1 (en) 2020-02-27 2021-09-02 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
WO2024108087A1 (en) 2022-11-18 2024-05-23 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
WO2024118740A1 (en) 2022-11-29 2024-06-06 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1080370A4 (en) 1998-05-29 2003-07-30 Epimmune Inc IDENTIFICATION OF RESILIENT DR EPITOPES LARGELY REACTIVE
WO2000057907A2 (en) * 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
AU4040400A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
AU3844101A (en) 2000-02-16 2001-08-27 Us Health Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (fr) * 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
ES2315221T3 (es) 2000-05-30 2009-04-01 Mahidol University Cepas atenuadas del virus del dengue y su utilizacion en una composicion vaccinea.
WO2003101397A2 (en) 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines
CN1234852C (zh) * 2003-01-30 2006-01-04 上海天甲生物医药有限公司 一种以登革热病毒重组复制子为载体的假病毒颗粒疫苗
BRPI0408774A (pt) 2003-03-24 2006-03-28 Scripps Research Inst vacinas de dna contra crescimento tumoral e seus usos
KR101536612B1 (ko) * 2005-06-17 2015-07-14 사노피 파스퇴르 약독화된 뎅기 혈청형 1 균주
KR101582163B1 (ko) * 2005-06-17 2016-01-05 사노피 파스퇴르 약독화된 뎅기 혈청형 2 균주
US20080193477A1 (en) * 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Also Published As

Publication number Publication date
US7718357B2 (en) 2010-05-18
JP2009542783A (ja) 2009-12-03
TW200813228A (en) 2008-03-16
AU2007274100B2 (en) 2013-02-07
MY169275A (en) 2019-03-21
BRPI0712878A2 (pt) 2012-09-04
MX2009000369A (es) 2009-01-29
AR061887A1 (es) 2008-10-01
EP2043680A1 (fr) 2009-04-08
FR2903605A1 (fr) 2008-01-18
WO2008007021A1 (fr) 2008-01-17
TWI400333B (zh) 2013-07-01
KR20090027759A (ko) 2009-03-17
CN101489585B (zh) 2013-12-04
US20100221285A1 (en) 2010-09-02
CN101489585A (zh) 2009-07-22
IL196331A0 (en) 2011-08-01
JP5295956B2 (ja) 2013-09-18
AU2007274100A1 (en) 2008-01-17
US20080014219A1 (en) 2008-01-17
CA2656349A1 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
ZA200900155B (en) Method of immunisation against the four serotypes of dengue
IL230052A0 (en) A method for vaccination against 4 serotypes of dengue
IL197768A0 (en) Immunisation method against the 4 dengue serotypes
HK1218427A1 (zh) 改進的疫苗及其使用方法
IL209188A (en) Sweetener, preparations containing it and methods of manufacture
GB2454149B (en) Refuge chamber and method
SI3136030T1 (sl) Postopek liofilizacije
ZA200805297B (en) Method of using ß-hydroxy-ß-methylbutyrate
GB0724319D0 (en) Methods & uses
GB0605247D0 (en) Compositions and methods for immunisation
GB0910201D0 (en) The preparation method of 2-deoxy-l-ribose
GB2455464B (en) Semiconductor and method for producing the same
EP2061506A4 (en) VACCINE COMPOSITION AND IMMUNIZATION METHOD
IL197022A0 (en) Novel preparation method
GB0620787D0 (en) Method and device for the selective isolation of serotypes
PL381051A1 (pl) Sposób stymulacji dojrzewania loszek
EP2204271A4 (en) PROCESS FOR INJECTING POLYVINYL ALCOHOL (PVA) PARTS AND PARTS SO OBTAINED
HU0600633D0 (en) Method of improving the effectiveness of advertisements
GB0614684D0 (en) Method and formulation for the prevention of cardiovascular disease
PL379394A1 (pl) Sposób ogrzewania zewnętrznych powierzchni, zwłaszcza poziomych i urządzenie do korzystania z tego sposobu
IL183169A0 (en) Ornament maunfactured using the capsulation method
PL1886669T3 (pl) Preparat o działaniu immunotropowym na bazie fosfoglukanu do leczenia przerostu migdałka gardłowego
AU313771S (en) Racquet
IL197925A0 (en) Method of micronization
PL381076A1 (pl) Sposób wytwarzania polimetylenomoczników